Landstar System reported a 25% increase in third-quarter 2026 revenue to $1.512 billion and a 154% rise in earnings per share to $1.42 compared to the same period last year. The growth was driven by a 29% increase in truck revenue and higher revenue per load, although earnings were impacted by elevated insurance and claim costs totaling $55.3 million. The company also added 165 Business Capacity Owner trucks, improving safety metrics despite industry challenges. Landstar continues to return capital to shareholders through share repurchases and dividends, with a strong balance sheet and plans to maintain quarterly dividends.
Landstar System's third-quarter 2026 results showed revenue of $1.512 billion and earnings per share of $1.42. For readers following the Industrials sector, here is Pluang's market snapshot as of Oct 28, 2026 03:12 WIB: 84 of 135 priced US Industrials stocks rose while 51 fell. Notable movers include Archer Aviation Inc (ACHR) at USD 4.25 with a 7.87% increase and 100% buy order activity on Pluang.
The global drone defense system market is projected to grow from $4.72 billion in 2025 to $18.19 billion by 2030, driven by increasing unauthorized drone incidents and demand for advanced detection and countermeasure technologies. Growth is fueled by...
Eli Lilly has outpaced Novo Nordisk in the GLP-1, obesity, and Type 2 Diabetes market, achieving a $1.21 trillion valuation. While Novo Nordisk's share price has fallen back after earlier gains and revenue growth remains flat, its management's strate...
argenx SE announced it will stop its Phase 3 UNITY study of efgartigimod subcutaneous for moderate-to-severe Sjögren's disease after an independent committee found the trial unlikely to meet its primary goal. This decision caused the company's stock ...
Pomerantz LLP is investigating DaVita Inc. for potential securities fraud following a sharp stock price drop triggered by a new U.S. federal strategy targeting the dialysis market. The Department of Health and Human Services announced a plan to incre...
Pomerantz LLP is investigating ClearPoint Neuro and its executives for possible securities fraud following a significant stock price drop. The decline occurred after ClearPoint's partner, uniQure, announced that their Huntington's disease treatment f...
